Smith+Nephew announced the results of its cash tender offer for up to $250 million of its outstanding 2.032% Senior Notes due 2030. The aggregate principal amount of notes validly tendered and not withdrawn was $431,825,000, exceeding the maximum tender amount and triggering a proration scaling factor of 57.995%. The company accepted $250,000,000 in principal amount at a consideration of U.S.$878.90 per U.S.$1,000 principal amount. Accepted notes will be canceled, and the settlement date is expected to be September 18, 2026. Smith+Nephew operates in the medical technology industry, focusing on the repair, regeneration, and replacement of soft and hard tissue through orthopaedics, sports medicine, and wound management products.

Smith+Nephew announced the pricing of a cash tender offer for up to $250 million of its outstanding 2.032% Senior Notes due 2030, which have an aggregate principal amount of $900 million outstanding. The company set the tender consideration at U.S.$878.90 per U.S.$1,000 principal amount, based on a fixed spread over the reference yield as of September 15, 2026. The offer expired on that date and is subject to proration if oversubscribed, with settlement expected on September 18, 2026. Smith+Nephew operates in the medical technology industry, focusing on the repair, regeneration, and replacement of soft and hard tissue through orthopaedics, sports medicine, and wound management products.

Smith & Nephew plc filed a Form 6-K to incorporate the Underwriting Agreement dated September 9, 2026, into its existing Registration Statement on Form F-3. The filing relates to the issuance of $700,000,000 aggregate principal amount of 5.750% Notes due in 2036. This debt offering represents a significant capital raising activity for the company. Smith & Nephew plc operates in the medical technology industry, developing and manufacturing orthopaedic, sports medicine, ENT, wound management, and plastic surgery products.

Smith & Nephew plc completed the pricing of a USD 700 million issuance of 5.750% Notes due in 2036, receiving net proceeds of approximately USD 690.9 million after underwriting discounts. The company intends to use these funds primarily to finance the purchase of its outstanding 2.032% Senior Notes due in 2030 through a tender offer and to cover related fees and expenses, with any remaining balance allocated for general corporate purposes. The transaction is scheduled to close on September 11, 2026, subject to customary conditions. Smith & Nephew operates as a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue through its orthopaedics, sports medicine, and wound management divisions.

Smith & Nephew plc priced a USD 700 million issuance of 5.750% Notes due 2036, with net proceeds of USD 690,928,000 after underwriting discounts. The company intends to use the majority of these funds to repurchase its outstanding 2.032% Senior Notes due 2030 via a tender offer and to cover related fees and expenses, while retaining the remainder for general corporate purposes. The transaction is scheduled to close on September 11, 2026, subject to customary conditions. Smith & Nephew operates in the medical technology industry, focusing on the repair, regeneration, and replacement of soft and hard tissue through orthopaedics, sports medicine, ENT, and advanced wound management products.